Earlier this year, Pfizer Canada, the pharmaceutical giant behind EpiPens, reported a shortage in both the 0.3 and 0.15-milligram versions of the drug. As the country’s only brand of life-saving epinephrine auto-injectors (EAIs), Pfizer’s announcement sent Health Canada scrambling for solutions as the shortage is predicted to persist into next[Read More…]
